The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
palivizumab · Injection, Solution
2 marketed package NDCs · 1 active manufacturer
What changed in the last 90 days
Every detected change for palivizumab, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- SynagisAug 12, 2026Mfr exitedSwedish Orphan Biovitrum AB (publ) · palivizumab
Same drug class
Other molecules FDA puts in Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Palivizumab in shortage right now?
- No. FDA does not currently list Palivizumab in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Palivizumab?
- 3 companies have marketed Palivizumab in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
Shortage reports for this molecule
- Planned discontinuation — Synagis, Injection, 100 mg/1 mL (NDC 66658-231-01)Aug 13, 2025
- Planned discontinuation — Synagis, Injection, 50 mg/.5 mL (NDC 66658-230-01)Aug 13, 2025
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.